Coherus Oncology

Coherus BioSciences will see 16% revenue growth driving future value

neofeudal

Not Invested

Community Contributor

Published

10 Feb 25

Updated

12 Mar 25

neofeudal's Fair Value

US$15.42

89.4% undervalued

12 Mar

US$1.64

60.8%

5.1%

60.8%

5.1%

You can edit this narrative until May 14 2:40 AM. Then, changes will post as Updates.

Author's Valuation

US$15.4289.4% undervalued

neofeudal's Fair Value

Narrative

Updates1

Shared on12 Mar 25

AlexanderD made no meaningful changes to valuation assumptions.

neofeudal'sFair Value

US$15.42

89.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

1.33%

Biotech revenue growth rate

8.50%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.07%

Calculation

US$126.61m

Earnings '29

26.23x

PE Ratio '29

US$3.32b

Market Cap '29

US$3.32b

Market Cap '29

129.94m

No. shares '29

US$25.56

Share Price '29

US$25.56 Share Price '29

Discounted to 2024 @ 10.63% p.a.

US$15.42

Fair Value '24